At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 201 enrolled
Drug / intervention
Dexcom G6device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Expanding Use of Continuous Glucose Monitoring Beyond COVID in Critical Care: Impact on Nurse Work Patterns and Patient Outcomes
In Brief
A Phase 2 clinical trial evaluating Dexcom G6 for Hyperglycemia. Completed, enrolled 201 participants across 1 site.
Detailed Summary
The primary objective of this implementation study is to assess the feasibility of real time continuous glucose monitoring (CGM) implementation using a CGM plus (+) point-of-care (POC) protocol among patients on IV insulin or those with hyperglycemia (\>250mg/dl) in the critical care hospital environments.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHyperglycemia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedOct 2022
Enrollment StartNov 2023
Primary CompletionSep 2024
TodayJul 2026
First PostedOct 7, 2022
Enrollment StartNov 1, 2023
Primary CompletionSep 19, 2024
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 3.7 years ago
Interventions
Dexcom G6device
Continuous Glucose Monitor